Study Title

18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers

Study Details

Description:

As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.

Sponsor:

First Affiliated Hospital of Fujian Medical University

Contacts:

Rong Lin, MD

linrong1214@foxmail.com

+86-0591-87981619

Weibing Miao, MD

miaoweibing@126.com

+86-0591-87981618

Government Study Link:

NCT06734572 - Click here to see study on

ClinicalTrials.gov

Drug Details

18F-FAPI-Biotin
Isotope(s):
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target(s):
  • FAP

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468